United States securities and exchange commission logo

                          February 2, 2021

       Gerrit Dispersyn, Dr. Med. Sc.
       Chief Executive Officer
       Phio Pharmaceuticals Corp.
       257 Simarano Drive, Suite 101
       Marlborough, MA 01752

                                                        Re: Phio
Pharmaceuticals Corp.
Statement on Form S-3
                                                            Filed January 29,
                                                            File No. 333-252588

       Dear Dr. Dispersyn:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Ada D.
Sarmento at 202-551-3798 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Ryan A. Murr, Esq.